Mark James Litton - 03 Mar 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Award	$0	+333,815		$0.000000	333,815	03 Mar 2025	Common Stock	333,815	$0.3762	Direct	F1
transaction	ATHA	Restricted Stock Units	Award	$0	+222,543		$0.000000	222,543	03 Mar 2025	Common Stock	222,543		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3	100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.